• Objectives -This analysis reviews the consistency of efficacy and safety results of 4 (two phase 2 and 2 phase 3) 12-week, vehicle-controlled studies (N = 1683) conducted during the development of IVM.
• Methods -Phase 2, Study 1 · 6-arm, 12 week, dose ranging, multicenter, randomized, investigator-blind, vehicleand active-controlled study -Ivermectin 0.1%, QD; Ivermectin 0.3%, QD; Ivermectin 1%, QD; Ivermectin 1%, BID ; Metronidazole 0.75%, BID; and Vehicle, QD · Subjects were male or female, ≥ 18 years of age, with PPR (≥ 15 lesions) · For the sake of consistency of this analysis, only data from the Ivermectin 1% and the vehicle QD arms are reported here. Figure 2 ).
Safety
• The treatment was highly tolerable in all 4 studies, and there were few study discontinuations (Table 1 
INTRODUCTION
• Rosacea is a chronic inflammatory disease.
• Rosacea has traditionally been classified as erythematotelangiectatic (ETR), papulopustular (PPR), phymatous, or ocular rosacea.
• PPR is characterized by facial papules, pustules, and persistent erythema.
• The pathogenesis of PPR is not yet completely understood; however, current studies indicate that underlying causes may include dysregulation of the innate immune system, overgrowth of commensal skin organisms, aberrant neurovascular signaling, and the production of inflammatory mediators in facial skin. 1 
